Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

News Release

Wave Life Sciences to Present at the Jefferies 2018 Healthcare Conference

May 31, 2018 at 5:11 PM EDT

CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2018 Healthcare Conference in New York on Tuesday, June 5, 2018 at 1:30 P.M. EDT.

A live webcast of the presentation will be available on the investor relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com.  A replay of the presentation will be archived and available at that site for a limited time following the event.

About Wave Life Sciences
Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Its chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. The company’s pipeline is initially focused on neurological disorders and extends across several other therapeutic areas. For more information, please visit www.wavelifesciences.com.

Investor Contact:

Jillian Connell
617-949-2981
jconnell@wavelifesci.com

Media Contact:

Jose Juves
617-949-4708
jjuves@wavelifesci.com

Patient Contact:

Wendy Erler
617-949-2898
werler@wavelifesci.com

Primary Logo

Source: Wave Life Sciences